Pipeline

Project

Area

Mode of Action

Phase I

Phase II

Phase III

Filing 

Eptinezumab (anti-CGRP mAb)* Migraine prevention

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine.

            

Brexpiprazole**

Agitation in Alzheimer’s disease

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors.

           

Brexpiprazole**

Post-Traumatic Stress Disorder

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors.

 

      

     

 
Brexpiprazole** Borderline Personality Disorder

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. 

           

Lu AF11167 (PDE 10 inhibitor)

Schizophrenia

Lu AF11167 is a small molecule and a potent and selective inhibitor of the phosphodiesterase 10A enzyme (PDE10Ai). It modulates dopamine D1 and D2 receptor-mediated intraneuronal signaling without binding to these receptors. The modulation of the dopaminergic function is believed to reduce negative symptoms and to keep positive symptoms stabilized.

 

     

   

Aripiprazole
2-month injectable formulation** 

Schizophrenia /Bipolar I disorder Aripiprazole is a small molecule. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonist at serotonin 5-HT2A receptors.             
Lu AG06466 (MAGL inhibitor)

Neurology/Psychiatry

Lu AG06466 is a small molecule, orally active and highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing 2-AG levels is a viable approach to restore brain homeostasis.

               

Lu AF82422 (alpha-synuclein mAb)

 

Synucleinopathies

 

 

Lu AF82422 is a monoclonal antibody targeting alpha-synuclein. Misfolding, aggregation and extracellular spreading of alpha-synuclein is believed to play a major role in disease pathology and progression in Parkinson’s disease and other neurodegenerative disorders.

           
Lu AF28996 (D1/D2 agonist)*** Parkinson’s Disease

Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.

           
Lu AF88434 (PDE1B inhibitor) Cognitive dysfunction

Lu AF88434 is a small molecule and a potent and selective PDE1B phosphodiesterase inhibitor which increases neuronal levels of cyclic nucleotide second messengers. Strengthening intracellular neuronal signaling by increasing neuronal levels of cyclic nucleotides may result in enhanced neuroplasticity/intracellular signaling and cognitive functioning.

           
Lu AG09222 (PACAP mAb) Migraine

LU AG09222 is a monoclonal antibody designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP) signaling for migraine prevention. PACAP has emerged as a signaling molecule in the pathophysiology of migraine.

           
Lu AF87908
(Tau mAb)
Tauopathies            

Lu AF87908 (Tau mAb) is a monoclonal antibody targeting the pathological form of the protein tau which is believed to play a pivotal role in the development and progression of Alzheimer’s disease and other neurodegenerative disorders.

     

 

   

* Filing stage ex-US

** In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. 

*** Explorative Phase 1b

 

 

 

 

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.